Exenatide does not promote weight loss in schizophrenia

Exenatide does not promote weight loss in schizophrenia

(HealthDay)—For antipsychotic-treated obese patients with schizophrenia, glucagon-like peptide-1 receptor agonists (GLP-1RAs) do not appear to promote weight loss, according to a study published online Sept. 26 in Diabetes, Obesity and Metabolism.

Pelle L. Ishøy, M.D., from the University of Copenhagen in Denmark, and colleagues examined the of the GLP-1RA exenatide once weekly in antipsychotic-treated obese patients with schizophrenia. Patients were randomized to three months of once-weekly injections of exenatide (23 patients) or placebo (22 patients). Forty patients completed the trial.

The researchers found that the exenatide and placebo groups experienced significant (P = 0.004) but similar (P = 0.98) weight losses (2.24±3.3 kg and 2.23±4.4 kg, respectively) after three months of treatment.

"Treatment with exenatide once-weekly did not promote in obese, antipsychotic-treated patients with schizophrenia compared to placebo," the authors write. "Our results could suggest that the body weight-lowering effect of GLP-1RAs involves dopaminergic signaling, but blockade of other receptor systems may also play a role. Nevertheless, anti-obesity regimens effective in the general population may not be readily implemented in antipsychotic-treated patients with ."

Several authors disclosed financial ties to pharmaceutical companies, including AstraZeneca, the manufacturer of exenatide.


Explore further

Exenatide twice daily deemed efficacious across BMI ranges

More information: Abstract
Full Text (subscription or payment may be required)

Copyright © 2016 HealthDay. All rights reserved.

Citation: Exenatide does not promote weight loss in schizophrenia (2016, October 5) retrieved 4 December 2021 from https://medicalxpress.com/news/2016-10-exenatide-weight-loss-schizophrenia.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors